High-potency active pharmaceutical ingredient (HPAPI) manufacturing continues to be an active area of investment by CDMOs/CMOs. DCAT Value Chain Insights analyzes key market drivers, including for antibody drug conjugates and other oncology…
Global Bio/Pharma Watch: Geographic Market Performance
What are the key happenings in the global bio/pharmaceutical industry from a market perspective? DCAT Value Chain Insights provides a view of key developments from across the globe impacting growth and industry…
Will the trend of combining API and drug-product development and manufacturing services into a “one-stop shop” business model for CDMOs continue? DCAT Value Chain Insights examines recent deals and investments. Tracking activity…
Which modality, small molecules or biologics, leads among the top-selling products? A look at the top-selling products industry-wide and blockbusters from select leading bio/pharma companies provides the answer. Modality of…
Biosimilars Market Outlook: Uptake Gains Momentum in US
By 2025, $112 billion of biologic medicines will lose exclusivity in the global market. Uptake of biosimilars will gain momentum, especially in the US, which has historically lagged compared to…
At the halfway point in 2021, how are approvals of new molecular entities (NMEs) by the FDA progressing, and how does it compare to prior years? What NMEs have been…
Market Watch: Cell and Gene Therapies, Niche But Growing
Cell and gene therapies are a niche, but growing part of the bio/pharma industry. DCAT Value Chain Insights looks at key market activity: number of developers, commercial products, pipelines, and…
The European Parliament formally approved last month the EU–UK pact under Brexit, which governs trade and customs issues. The pact has been applied conditionally since the beginning of 2021, but…
AstraZeneca’s $39-Bn Buy of Alexion: Will It Pay Off?
AstraZeneca took a step forward in its $39-billion acquisition of Alexion Pharmaceuticals with approval of the deal from the US Federal Trade Commission last month. The deal, which is expected…
The Pharma Pulse: Product Innovation & Emerging Pharma
New product development is the lifeblood of any industry. Smaller bio/pharmaceutical companies are accounting for an increasingly larger portion of new products as measured by recent new molecular entity approvals.…
